Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update

A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma

(2021) Di Wang et al.   BLOOD

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

(2021) Philippe Moreau et al.   LANCET ONCOLOGY

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

(2021) Luciano J. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

(2021) Mounzer E. Agha et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.

(2021) Matthew J. Frigault et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

(2021) Nizar J. Bahlis et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

(2021) Amrita Y. Krishnan et al.   JOURNAL OF CLINICAL ONCOLOGY

The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.

(2021) Lu Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma.

(2021) Hua Jiang et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.

(2021) Salomon Manier et al.   JOURNAL OF CLINICAL ONCOLOGY

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

(2021) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

(2021) Jesus G. Berdeja et al.   JOURNAL OF CLINICAL ONCOLOGY

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

(2021) Larry D. Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma

(2021) Lu Han et al.   LEUKEMIA

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

(2020) Lingzhi Yan et al.   BLOOD

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

(2020) Bai-Yan Wang et al.   BLOOD

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

(2020) Chenggong Li et al.   BLOOD

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

(2020) Luciano J. Costa et al.   BLOOD

A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA

(2020) Kodandaram Pillarisetti et al.   BLOOD

Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma

(2020) Xin Yao et al.   BLOOD

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

(2020) Jesus G. Berdeja et al.   BLOOD

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

(2020) Norris Lam et al.   Nature Communications

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

(2020) Nikhil C. Munshi et al.   JOURNAL OF CLINICAL ONCOLOGY

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

(2020) Sham Mailankody et al.   JOURNAL OF CLINICAL ONCOLOGY

Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).

(2020) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.

(2020) Adam D. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

(2020) Hans C. Lee et al.   LEUKEMIA

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

(2020) Chiara Caraccio et al.   Frontiers in Immunology

B-cell maturation antigen expression across hematologic cancers: a systematic literature review

(2020) Ahmet Dogan et al.   Blood Cancer Journal

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions

(2020) Luis Gerardo Rodríguez-Lobato et al.   Frontiers in Oncology

Immune-based therapies in the management of multiple myeloma

(2020) Saurabh Zanwar et al.   Blood Cancer Journal

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

(2020) Lingzhi Yan et al.   Cancer Medicine

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

(2019) Eric L. Smith et al.   Science Translational Medicine

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

(2019) Sundar Jagannath et al.   Clinical Lymphoma Myeloma & Leukemia

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer

(2019) Steven Feins et al.   AMERICAN JOURNAL OF HEMATOLOGY

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

(2019) Dennis Cooper et al.   BLOOD

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

(2019) Rakesh Popat et al.   BLOOD

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

(2019) Jin Jie et al.   BLOOD

A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

(2019) Hua Zhang et al.   BLOOD

How to Train your T cells: Overcoming Immune Dysfunction in Multiple Myeloma

(2019) Adam D Cohen et al.   CLINICAL CANCER RESEARCH

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

(2019) Zhiling Yan et al.   Lancet Haematology

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy

(2018) Elena Zamagni et al.   Expert Review of Hematology

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-Agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56 Positive Multiple Myeloma

(2018) Sikander Ailawadhi et al.   Clinical Lymphoma Myeloma & Leukemia

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

(2018) Suzanne Trudel et al.   LANCET ONCOLOGY

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

(2018) Susanne H. Baumeister et al.   Cancer Immunology Research

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

Immunotoxin: A new tool for cancer therapy

(2017) Hossein Allahyari et al.   TUMOR BIOLOGY

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

(2016) Y.-T. Tai et al.   BLOOD

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

(2016) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

CAR models: next-generation CAR modifications for enhanced T-cell function

(2016) Daniel Abate-Daga et al.   Molecular Therapy-Oncolytics

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

(2015) Jessica R. McCombs et al.   AAPS Journal

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

(2015) C. Peters et al.   BIOSCIENCE REPORTS

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

(2015) Alfred L. Garfall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells

(2013) Yossi Cohen et al.   Hematology

Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow

(2012) K. Boucher et al.   CLINICAL CANCER RESEARCH

Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma

(2012) P C Schuberth et al.   GENE THERAPY

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma

(2012) K. Elkins et al.   MOLECULAR CANCER THERAPEUTICS